Bone marrow transplant shows signs of curing brave little boy with one in a million condition – Shields Gazette

One-year-old Max Gardner was diagnosed with aplastic anaemia, in October 2020, a serious condition in which the bone marrow and stem cells do not produce enough blood cells.

After Max developed significant bruises and a rash over his body, parents, Connor Gardner and Rachel Nicholson, from Hebburn, were referred to South Tyneside District Hospital, where their brave little boy underwent tests.

Doctors initially believed that Max had an immune disorder but after he was admitted to the Royal Victoria Infirmary (RVI) further tests helped to diagnose him with aplastic anaemia.

Read More

The family was told that the condition could be fatal if not treated properly.

Doctors said Max needed to have a bone marrow transplant, which has the potential to cure him.

Dad Connor, 29, and mum Rachel, 27, were both tested to see if they would be a bone marrow match and the pair were overjoyed when Rachel was found to be a 9/10 match.

Max started chemotherapy on January 7 at the RVI and mum Rachel donated stem cells on January 13 at Newcastles Freeman Hospital.

The following day, January 14, Max underwent the transplant at the RVI.

The family is now waiting for the results of a Chimerism Test which will tell them for definite whether the stem cells have worked but signs are already looking positive.

Delighted dad, Connor, said: "His neutrophils [a type of white blood cell that protect us from infections] have been more than 0.50 for three days in a row, which means that he is essentially engrafted, which means that his body is accepting the transplant.

"So it is working, but we still have to wait for the test results."

Doctors say there is no doubt that it has worked with the way the numbers have gone up but they have to officially do it like that to make sure, Connor continued.

"But there is no reason why it shouldnt have [doctors] say.

"He has done really well to get to this stage, he has absolutely sailed through it, everyone is surprised with how well he has done.

This the best outcome we could have hoped for.

But it hasnt been plain sailing for the family, who have also had to face additional challenges during the treatment.

Parents Connor and Rachael initially were not allowed to visit Max at the same time due to Covid rules, however the hospital has now eased the restriction in their case.

The family also became sick with Norovirus in the run-up to the transplant, causing concern over whether it would have to be pushed back.

Thankfully, the transplant went ahead as planned and the family made a good recovery, although Max still needs help with his eating.

Max will now have to remain in hospital for a while longer as he recovers from the transplant.

Connor added: We can feel that we are nearly at the end of it.

"His neutrophils are the highest they have ever been since he became poorly so we feel like we are coming to the end.

See original here:
Bone marrow transplant shows signs of curing brave little boy with one in a million condition - Shields Gazette

Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day

AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Citi’s 2021 Virtual Immuno-Oncology Day Conference being held virtually February 17-18, 2021.

Read more here:
Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day

Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering

TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has closed its previously announced bought deal prospectus offering of 46,000,000 units (“Units”) at a price of $0.50 per Unit for aggregate gross proceeds of $23,000,000 (the “Offering”), which includes the exercise in full of the 15% over-allotment option. The syndicate of underwriters was led by Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (together, the "Underwriters"). The Units were offered and sold by way of a short form prospectus filed with the securities commissions in each of the provinces of Canada, other than Québec.

See the article here:
Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering

Trading in Novo Nordisk shares by board members, executives and associated persons on 11-12 February 2021

Bagsværd, Denmark, 12 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

View original post here:
Trading in Novo Nordisk shares by board members, executives and associated persons on 11-12 February 2021

Tauriga Sciences Inc. to Commence Development of its 1st Full Spectrum CBD Infused Edibles Product Line

NEW YORK, NY , Feb. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as an ongoing Pharmaceutical Development initiative, today announced that it has commenced development of its 1st full spectrum Cannabidiol (“CBD”) infused edibles product line.  The Company plans to develop this above referenced product line, with the following attributes: Kosher Certified, Halal Certified, Vegan Formulation, Dairy-Free, Infused with Full Spectrum Hemp Extract (“Full Spectrum”), All-Natural Flavors, Sugar Free/Diabetic Friendly Version(s), and Full Adherence to U.S. Federal Laws & Regulations.  The Company expects to provide concrete details about this proposed full spectrum product line within the near term.

Read the original:
Tauriga Sciences Inc. to Commence Development of its 1st Full Spectrum CBD Infused Edibles Product Line

New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three…

In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results of ABO-102 in MPS IIIA and ABO-101 in MPS IIIB continue to show dose-dependent and sustained reductions in disease-specific biomarkers, denoting clear biologic effects

Read the rest here:
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three...

Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase…

LONDON and REDWOOD CITY, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the closing of its previously announced underwritten public offering of 39,675,000 American Depositary Shares (“ADSs”), at a public offering price of $2.90 per ADS, which includes 5,175,000 additional ADSs issued upon the exercise in full of the underwriters’ option to purchase additional ADSs. Each ADS represents five ordinary shares of Mereo. The aggregate gross proceeds to Mereo from the offering, before deducting underwriting discounts and commissions and offering expenses were $115.1 million. All of the ADSs in the offering were sold by Mereo.

Visit link:
Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase...